Xilio Therapeutics Inc (XLO)

Apr 04, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 04, 2025

Apr 04, 2025

Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan

Apr 04, 2025

Apr 02, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World

Apr 02, 2025

Mar 31, 2025

Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World

Mar 31, 2025

Mar 25, 2025

Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World

Mar 25, 2025

Mar 20, 2025

Deals In Depth: February 2025 - insights.citeline.com

Mar 20, 2025

Mar 18, 2025

Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Mar 18, 2025

Mar 13, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

Mar 13, 2025

Mar 12, 2025

Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks

Mar 12, 2025

Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK

Mar 11, 2025

Mar 11, 2025

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025

Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq

Mar 11, 2025

Mar 04, 2025

Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily

Mar 04, 2025

Feb 28, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World

Feb 28, 2025

Feb 24, 2025

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 24, 2025

Feb 24, 2025

Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan

Feb 24, 2025

Feb 22, 2025

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World

Feb 22, 2025

Feb 20, 2025

Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN

Feb 20, 2025

Feb 19, 2025

Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle

Feb 19, 2025

Feb 18, 2025

Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com

Feb 18, 2025

Feb 17, 2025

Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat

Feb 17, 2025

Feb 14, 2025

Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn

Feb 14, 2025

Feb 14, 2025

Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP

Feb 14, 2025

Feb 14, 2025

Xilio shares soar on AbbVie collaboration deal - MSN

Feb 14, 2025

Feb 14, 2025

AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE

Feb 14, 2025

Feb 14, 2025

Top Biotech Stocks To Keep An Eye On – February 12th - Defense World

Feb 14, 2025

Feb 13, 2025

AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights

Feb 13, 2025

Feb 13, 2025

Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld Online

Feb 13, 2025

Feb 13, 2025

Xilio Therapeutics: Innovative TCE Platform and Strategic AbbVie Partnership Justify Buy Rating - TipRanks

Feb 13, 2025

Feb 13, 2025

AbbVie and Xilio Therapeutics announce collaboration and option agreement - MSN

Feb 13, 2025

Feb 13, 2025

We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - Simply Wall St

Feb 13, 2025

Feb 13, 2025

Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals

Feb 13, 2025

Feb 13, 2025

AbbVie partners with Xilio to develop tumour-activated immunotherapies - World Pharmaceutical Frontiers

Feb 13, 2025

Feb 13, 2025

AbbVie and Xilio to collaborate on antibody-based immunotherapies - Yahoo Finance

Feb 13, 2025

Feb 13, 2025

AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio - sharewise

Feb 13, 2025

Feb 12, 2025

Xilio Gains 125% on New Deal with AbbVie to Target Prostate and Other Cancers - PUNE.NEWS

Feb 12, 2025

Feb 12, 2025

AbbVie pens another T cell engager deal, this time with Xilio - Endpoints News

Feb 12, 2025

Feb 12, 2025

AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace

Feb 12, 2025

Feb 12, 2025

Xilio soars after tie-up with AbbVie to develop cancer treatments - TradingView

Feb 12, 2025

Feb 12, 2025

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga

Feb 12, 2025

Feb 12, 2025

Stock market today: Spire Global plunged by 48.97% while Xilio Therapeutics surged by 102.16% in early trading - Business Upturn

Feb 12, 2025

Feb 12, 2025

AbbVie inks another billion-dollar oncology deal - Crain's Chicago Business

Feb 12, 2025

Feb 12, 2025

AbbVie, Xilio Hook up - Baystreet.ca

Feb 12, 2025